Pharvaris N v (PHVS) - News Archive

Pioneering Advances in Bradykinin-Mediated Angioedema: Pharvaris Unveils Promising Data on DeucrictibantIn a significant stride towards addressing the unmet medical needs of patients with bradykinin-mediated disorders,...

ZUG, Switzerland April 1, 2025 Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing innovative therapies for bradykinin-mediated diseases, has announced that the European Commission (EC...

Pharvaris Charts a Course for Strategic Growth Amidst Financial ChallengesOverview of Pharvaris’ Strategic Vision for 2025ZUG, Switzerland – On January 13, 2025, Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Pharvaris Presents Encouraging Long-Term Data on Deucrictibant at Bradykinin Symposium 2024 Pharvaris (Nasdaq: PHVS), a biopharmaceutical company focused on developing new oral treatments for hereditary angioedema (HAE)...

ZUG, Switzerland - The late-stage biopharmaceutical enterprise with operations in Zug, Switzerland, Pharvaris, renowned for its development of groundbreaking, oral bradykinin B2 receptor antagonists to curb and prohibit...

Pharvaris Appoints Seasoned Financial Expert as Chief Financial OfficerZUG, Switzerland, April 10, 2024 - Pharvaris, a leading biopharmaceutical company specializing in the development of innovative oral bradykinin B2 r...

Pharvaris, a leading biopharmaceutical company focused on developing innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, recently presented promisi...

Pharvaris, a clinical-stage biopharmaceutical company, has announced that it will be presenting clinical data on their novel oral bradykinin B2 receptor antagonists at two upcoming congresses. The abstracts have been ac...

Swiss biotech firm Pharvaris has made a significant advance in the field of hereditary angioedema (HAE) treatments, recently showcasing its clinical data and analysis of Deucrictibant for on-demand treatment of HAE at t...

ZUG, Switzerland, Dec. 06, 2023 - Pharvaris N.V. (Nasdaq: PHVS), a clinical-stage biopharmaceutical company specializing in the development of novel oral bradykinin B2 receptor antagonists for addressing hereditary angi...

ZUG, Switzerland - Pharvaris (Nasdaq: PHVS), a clinical-stage company dedicated to developing novel, oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, has r...

Pharvaris, a clinical-stage company specializing in the development of innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, recently made an excitin...

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific MeetingZUG, Switzerland, Nov. 09, 2023 - Pharvaris (Nasdaq: PHVS), a clinical-stage company f...